KIF1B and sarcopenia: The convergence of these documented therapeutic properties with the KLP-KM2-mediated alterations in gut microbiota composition observed in our human trial suggests significant potential for KLP-KM2 as a safe postbiotic intervention in the management of sarcopenia, characterized by age-associated decline in muscle mass, strength, and function.